Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - FigS9 by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S15 by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S3 by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S1 by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S4 by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S5 by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S16 by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S12.tiff by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S6 by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - FigS13 by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S10 by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - FigS14_OS.tiff by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S2 by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis - Fig S8 by Fatih M Uckun (13809802)

“…Methods: We used the LPS plus D-galactosamine mouse model of sepsis to compare the anti-inflammatory activities of RJX, dexamethasone and a combination of RJX plus DEX. Additionally, we examined the clinical feasibility and tolerability of combining RJX with DEX in COVID-19 patients in a clinical phase I study. …”

Modeling Li-Ion Battery Voltage Oscillations and the Impact of Exchange Current Density on Oscillation Properties by Eduardo Parma (13047998)

DNA concentrations of ucfDNA in WT, <i>Dnase1l3</i>^-/- and <i>Dnase1</i>^-/- mice. by Meihui Chen (1670020)

Immunity triggered by silencing <i>NbUCH</i> does not require <i>NbPtr1.</i> by Wenjia Yu (9422059)

Table_1_The Silent Epidemic of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Children and Adolescents in Italy During the COVID-19 Pandemic in 2020.docx by Valentino Cherubini (9141940)

“…</p>Methods<p>Forty-seven pediatric diabetes centers caring for >90% of young people with diabetes in Italy recruited 4,237 newly diagnosed children with type 1 diabetes between 2017 and 2020 in a longitudinal study. Four subperiods in 2020 were defined based on government-imposed containment measures for COVID-19, and the frequencies of DKA and severe DKA compared with the same periods in 2017-2019.…”

Table_1_The Silent Epidemic of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Children and Adolescents in Italy During the COVID-19 Pandemic in 2020.docx by Valentino Cherubini (9141940)

“…</p>Methods<p>Forty-seven pediatric diabetes centers caring for >90% of young people with diabetes in Italy recruited 4,237 newly diagnosed children with type 1 diabetes between 2017 and 2020 in a longitudinal study. Four subperiods in 2020 were defined based on government-imposed containment measures for COVID-19, and the frequencies of DKA and severe DKA compared with the same periods in 2017-2019.…”

Colocalization of Sig1R-YFP with immunostained ER and mitochondria on fixed and permeabilized SK-OV-3 cells. by Sergei Kopanchuk (6406085)